June 07, 2016
The first release of HipSci proteomics mass spectrometry data is now publicly available.
This pilot data submission supports the proteomics analyses in our recent paper Common genetic variation drives molecular heterogeneity in human iPSCs. This represents the first of many data releases that HipSci will make for raw and analyses proteomics data.
May 26, 2016
Here, we describe the systematic generation, genotyping and phenotyping of 522 open access human iPSCs derived from 189 healthy male and female individuals.
Our study provides a comprehensive picture of the major sources of genetic and phenotypic variation in iPSCs and establishes their suitability for use in genetic studies of complex human traits and cancer.
April 15, 2016
High Content Review (HCR) has published an interview with Dr. Davide Danovi, the Director of HipSci Cell Phenotyping at the Centre for Stem Cells and Regenerative Medicine at King’s College London (KCL) and Dr. Reena Halai, the Project Manager of HipSci at the Wellcome Trust Sanger Institute.
Davide and Reena discuss the goals of the HipSci project, the findings of the cellular phenotyping project at KCL, and access to cell lines and data for iPSC researchers.
February 04, 2016
The first five IPS cell lines from HipSci are now available from ECACC. Scientists can now obtain quality-certified HipSci cell lines to conduct their own academic research.
Take a look at the ECACC website to see the HipSci collection.
HipSci has a banking arrangement with ECACC (European Collection of Cell Cultures) for distribution of all our IPS cell lines to academic researchers. This first release of five cell lines is just the start of our commitment to making all HipSci IPS cell lines available in this way. Over 50 additional lines are going through final tests prior to making them available.
HipSci has a separate banking arrangement with EBiSC for the disribution of some cell lines to commercial (as well as academic) researchers. If you are a commercial researcher then check back here soon for further announcements.
Cells lines in our HipSci data browser are marked with their current ‘banking status’. You can filter to display only lines that are currently available from ECACC.
If you require a large panel of different HipSci lines (20 plus) then contact ECACC (email@example.com) for a special quotation.
April 28, 2015
This call is now closed
We are looking to hear from clinicians (or scientist with access to relevant patient cases) working with patients with inherited genetic diseases, where a collection of disease causing mutations has already been identified, and the group would be interested in having iPS lines generated from some of your patients that you would use in further studies.
Please note that at this stage this is only an Expression of Interest and not a final call for proposals. The results will allow us to plan the use our remaining resources most efficiently.
Please contact us if you have a group of (between 10 and 50) patients with related phenotypes where you would be able to provide us with patient material (either fibroblasts or a skin biopsy).
Please see the HipSci Rare Disease Expression of interest page for more information. The details can also be found in the Expression of Interest PDF. The Expression of Interest should be submitted to firstname.lastname@example.org before 3rd July 2015.
March 20, 2014
We are seeking clinicians (or scientists with access to relevant patient cases) to provide samples from patients with inherited genetic diseases for the disease component of the HipSci project. We request that samples are provided in groups of between 10 and 50 with related phenotypes, and that all samples already have the genetic defect identified (the aim is to support gene analysis rather than gene discovery), with typically multiple cases with defects in the same gene. We encourage clinicians/scientists with only small numbers of samples to form larger groups with others who can contribute similar cases.
If you wish to submit a proposal or have any questions please email email@example.com Full Details can be found on the iPS cells for Rare disease cases: call for proposals page and in the Proposal PDF
November 06, 2012
The Wellcome Trust and Medical Research Council (MRC) today announced a £12.75 million initiative to create a catalogue of high-quality adult stem cells, so-called induced pluripotent stem cells (iPS cells). The initiative will provide a knowledge-base to underpin the use of such cells in studying the effects of our genes on health and disease and lay the foundations to create a new iPS cell bank, providing a world-class resource for UK researchers.